Compare Illumina, Inc. (ILMN) vs Manhattan Associates Inc (MANH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Manhattan Associates Inc — how do they compare? Illumina, Inc. trades at $191.86 (market cap $29.12B), while Manhattan Associates Inc trades at $189.83 (market cap $11.38B). The key difference: Illumina, Inc. is far larger — about 2.6× Manhattan Associates Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Manhattan Associates Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | MANH | |
|---|---|---|
Market Cap | $29.12B | $11.38B |
Sector | Health | Technology |
52-Week High | $205.10 | $220.19 |
52-Week Low | $91.00 | $120.88 |
Enterprise Value | $30.48B | $11.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Manhattan Associates Inc
Manhattan Associates, Inc. is a global leader in supply chain and omnichannel commerce software. The company provides a comprehensive suite of cloud-based and on-premise solutions for warehouse management (WMS), transportation management (TMS), and order management (OMS). MANH's technology helps retailers, wholesalers, and manufacturers manage inventory, optimize logistics, and unify the shopping experience across physical and digital channels.
Read more on MANH →
